Nemaura Medical evaluates new applications for continuous lactate monitoring using its BEAT platform

Nemaura Medical Inc (NASDAQ:NMRD), a medtech company developing micro-systems based wearable diagnostic devices, revealed Tuesday that iti s evaluating new applications for continuous lactate monitoring (CLM) using its BEAT platform to keep tabs on disease progression in coronavirus (Covid-19) patients. The Loughborough, UK-based company has issued a presentation clearly outlining the potential new application for Covid-19 patients using a CLM product. Nemaura had previously talked about the market for athletic performance monitoring using its non-invasive continuous lactate monitor. Based on recently published independent clinical evaluations, the “measurement of blood lactic acid has been established as an indicator for disease progression in Covid-19 patients,” noted the company. READ: Nemaura Medical files premarket application for sugarBEAT glucose monitor with FDA Nemaura has developed SugarBEAT, the world’s first non-invasive continuous glucose monitor for people with diabetes and pre-diabetes. Both sugarBEAT and the company’s new CLM products are based on Nemaura’s BEAT platform, which is designed to non-invasively extract a number of analytes through the skin. Nemaura said that by adapting the “sensor chemistry, algorithm and mobile app interface” initially developed for sugarBEAT, the BEAT platform has the potential to be utilized for “several markets beyond glucose monitoring and diabetes.” Nemaura said that it is "evaluating the timelines" for bringing the CLM product to market "as a Class 2 approved medical device." The genius of SugarBEAT lies in its skin-patch technology which allows for better glucose management. SugarBEAT consists of a daily disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings every five minutes for up to 24 hours.  The company is commercializing sugarBEAT together with its BEATdiabetes health subscription service aimed at people with Type 2 diabetes and prediabetes. Contact the author Uttara Choudhury at uttara@proactiveinvestors.com Follow her on Twitter: @UttaraProactive